Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency

Arthritis Research and Therapy

Volumn 15, Issue 1, 2013, Pages

  Martin, Praxedis ^a,b   Talabot Ayer, Dominique ^a,b   Seemayer, Christian A ^c   Vigne, Solenne ^a,b   Lamacchia, Céline ^a,b   Rodriguez, Emiliana ^a,b   Finckh, Axel ^a   Smith, Dirk E ^d   Gabay, Cem ^a,b   Palmer, Gaby ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^c NOVARTIS PHARMA AG   (Switzerland)

^d AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; INTERLEUKIN 33; IL1RL1 PROTEIN, MOUSE; INTERLEUKIN DERIVATIVE; INTERLEUKIN RECEPTOR; INTERLEUKIN-33, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE INDUCTION; GENOTYPE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; INTERLEUKIN 33 DEFICIENCY; KNOCKOUT GENE; MICROSATELLITE MARKER; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SYNOVIUM; WILD TYPE; ANIMAL; C57BL MOUSE; DEFICIENCY; EXPERIMENTAL ARTHRITIS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; GENOTYPE; IMMUNOHISTOCHEMISTRY; INTERLEUKINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, INTERLEUKIN;

EID: 84872187641     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4143     Document Type: Article

References (52)

1. Palmer G, Gabay C. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 2011, 7:321-329. 10.1038/nrrheum.2011.53, 21519352.
2. Lipsky BP, Toy DY, Swart DA, Smithgall MD, Smith D. Deletion of the ST2 proximal promoter disrupts fibroblast-specific expression but does not reduce the amount of soluble ST2 in circulation. Eur J Immunol 2012, 42:1863-1869. 10.1002/eji.201142274, 22585662.
3. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007, 282:26369-26380. 10.1074/jbc.M704916200, 17623648.
4. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490. 10.1016/j.immuni.2005.09.015, 16286016.
5. Humphreys NE, Xu D, Hepworth MR, Liew FY, Grencis RK. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol 2008, 180:2443-2449.
6. Pushparaj PN, Tay HK, H'Ng SC, Pitman N, Xu D, McKenzie A, Liew FY, Melendez AJ. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA 2009, 106:9773-9778. 10.1073/pnas.0901206106, 2700978, 19506243.
7. Kondo Y, Yoshimoto T, Yasuda K, Futatsugi-Yumikura S, Morimoto M, Hayashi N, Hoshino T, Fujimoto J, Nakanishi K. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol 2008, 20:791-800. 10.1093/intimm/dxn037, 18448455.
8. Alves-Filho JC, Sonego F, Souto FO, Freitas A, Verri WA, Auxiliadora-Martins M, Basile-Filho A, McKenzie AN, Xu D, Cunha FQ, Liew FY. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med 2010, 16:708-712. 10.1038/nm.2156, 20473304.
9. Le HT, Tran VG, Kim W, Kim J, Cho HR, Kwon B. IL-33 priming regulates multiple steps of the neutrophil-mediated anti-candida albicans response by modulating TLR and dectin-1 signals. J Immunol 2012, 189:287-295. 10.4049/jimmunol.1103564, 22661085.
10. Moussion C, Ortega N, Girard J-P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'?. PLoS ONE 2008, 3:e3331. 10.1371/journal.pone.0003331, 2556082, 18836528.
11. Pichery M, Mirey E, Mercier P, Lefrancais E, Dujardin A, Ortega N, Girard JP. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel IL-33-LacZ gene trap reporter strain. J Immunol 2012, 188:3488-3495. 10.4049/jimmunol.1101977, 22371395.
12. Bonilla WV, Frohlich A, Senn K, Kallert S, Fernandez M, Johnson S, Kreutzfeldt M, Hegazy AN, Schrick C, Fallon PG, Klemenz R, Nakae S, Adler H, Merkler D, Lohning M, Pinschewer DD. The alarmin interleukin-33 drives protective antiviral CD8 T cell responses. Science 2012, 335:984-989. 10.1126/science.1215418, 22323740.
13. Matsuyama Y, Okazaki H, Tamemoto H, Kimura H, Kamata Y, Nagatani K, Nagashima T, Hayakawa M, Iwamoto M, Yoshio T, Tominaga S, Minota S. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol 2010, 37:18-25. 10.3899/jrheum.090492, 19918048.
14. Mu R, Huang HQ, Li YH, Li C, Ye H, Li ZG. Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis. J Rheumatol 2010, 37:2006-2013. 10.3899/jrheum.100184, 20682660.
15. Hong YS, Moon SJ, Joo YB, Jeon CH, Cho ML, Ju JH, Oh HJ, Heo YJ, Park SH, Kim HY, Min JK. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci 2011, 26:1132-1139. 10.3346/jkms.2011.26.9.1132, 3172648, 21935266.
16. Carriere V, Roussel L, Ortega N, Lacorre D-A, Americh L, Aguilar L, Bouche G, Girard J-P. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 2007, 104:282-287. 10.1073/pnas.0606854104, 1765450, 17185418.
17. Talabot-Ayer D, McKee T, Gindre P, Bas S, Baeten DL, Gabay C, Palmer G. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine 2012, 79:32-37. 10.1016/j.jbspin.2011.02.011, 21441054.
18. Leung BP, Xu D, Culshaw S, McInnes IB, Liew FY. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 2004, 173:145-150.
19. Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR, Pitman N, Kurowska-Stolarska M, McKenzie AN, McInnes IB, Liew FY. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA 2008, 105:10913-10918. 10.1073/pnas.0801898105, 2491487, 18667700.
20. Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, Finckh A, Smith DE, Gabay C. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum 2009, 60:738-749. 10.1002/art.24305, 19248109.
21. Verri WA, Souto FO, Vieira SM, Almeida SC, Fukada SY, Xu D, Alves-Filho JC, Cunha TM, Guerrero AT, Mattos-Guimaraes RB, Oliveira FR, Teixeira MM, Silva JS, McInnes IB, Ferreira SH, Louzada-Junior P, Liew FY, Cunha FQ. IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann Rheum Dis 2010, 69:1697-1703. 10.1136/ard.2009.122655, 20472598.
22. Xu D, Jiang HR, Li Y, Pushparaj PN, Kurowska-Stolarska M, Leung BP, Mu R, Tay HK, McKenzie AN, McInnes IB, Melendez AJ, Liew FY. IL-33 exacerbates autoantibody-induced arthritis. J Immunol 2010, 184:2620-2626. 10.4049/jimmunol.0902685, 20139274.
23. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 2011, 475:110-113. 10.1038/nature10134, 21685887.
24. Ngoi SM, St Rose MC, Menoret AM, Smith DE, Tovey MG, Adler AJ, Vella AT. Presensitizing with a Toll-like receptor 3 ligand impairs CD8 T-cell effector differentiation and IL-33 responsiveness. Proc Natl Acad Sci USA 2012, 109:10486-10491. 10.1073/pnas.1202607109, 3387033, 22689946.
25. Townsend MJ, Fallon PG, Matthews DJ, Jolin HE, McKenzie AN. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med 2000, 191:1069-1076. 10.1084/jem.191.6.1069, 2193113, 10727469.
26. Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C, Mathis D. Organ-specific disease provoked by systemic autoimmunity. Cell 1996, 87:811-822. 10.1016/S0092-8674(00)81989-3, 8945509.
27. Towne JE, Renshaw BR, Douangpanya J, Lipsky BP, Shen M, Gabel CA, Sims JE. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity. J Biol Chem 2011, 286:42594-42602. 10.1074/jbc.M111.267922, 3234937, 21965679.
28. Beamer CA, Girtsman TA, Seaver BP, Finsaas KJ, Migliaccio CT, Perry VK, Rottman JB, Smith DE, Holian A. IL-33 mediates multi-walled carbon nanotube (MWCNT)-induced airway hyper-reactivity via the mobilization of innate helper cells in the lung. Nanotoxicology 2012,
29. Korganow AS, Ji H, Mangialaio S, Duchatelle V, Pelanda R, Martin T, Degott C, Kikutani H, Rajewsky K, Pasquali JL, Benoist C, Mathis D. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 1999, 10:451-461. 10.1016/S1074-7613(00)80045-X, 10229188.
30. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Francon B, Martin T, Gretener D, Perrin D, Leroy D, Vitte PA, Hirsch E, Wymann MP, Cirillo R, Schwarz MK, Rommel C. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005, 11:936-943.
31. Vigne S, Palmer G, Lamacchia C, Martin P, Talabot-Ayer D, Rodriguez E, Ronchi F, Sallusto F, Dinh H, Sims JE, Gabay C. IL-36R ligands are potent regulators of dendritic and T cells. Blood 2011, 118:5813-5823. 10.1182/blood-2011-05-356873, 21860022.
32. Lamacchia C, Palmer G, Gabay C. Discrimination of C57BL/6J Rj and 129S2/SvPasCrl inbred mouse strains by use of simple sequence length polymorphisms. J Am Assoc Lab Anim Sci 2007, 46:21-24.
33. Mouse Genome Informatics. , http://www.informatics.jax.org/
34. Rabe-Hesketh S, Skrondal A. Higher level models and nested random effects Multilevel and Longitudinal Modeling Using Stata 2005, 217-264. Texas: Stata Press.
35. Rijli FM, Dolle P, Fraulob V, LeMeur M, Chambon P. Insertion of a targeting construct in a Hoxd-10 allele can influence the control of Hoxd-9 expression. Dev Dyn 1994, 201:366-377. 10.1002/aja.1002010408, 7894075.
36. Pham CT, MacIvor DM, Hug BA, Heusel JW, Ley TJ. Long-range disruption of gene expression by a selectable marker cassette. Proc Natl Acad Sci USA 1996, 93:13090-13095. 10.1073/pnas.93.23.13090, 24051, 8917549.
37. Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, Gravallese E, Mathis D, Benoist C. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med 2002, 196:77-85. 10.1084/jem.20020439, 2194010, 12093872.
38. Bygrave AE, Rose KL, Cortes-Hernandez J, Warren J, Rigby RJ, Cook HT, Walport MJ, Vyse TJ, Botto M. Spontaneous autoimmunity in 129 and C57BL/6 mice-implications for autoimmunity described in gene-targeted mice. PLoS Biol 2004, 2:E243. 10.1371/journal.pbio.0020243, 509305, 15314659.
39. Kayagaki N, Warming S, Lamkanfi M, Vande Walle L, Louie S, Dong J, Newton K, Qu Y, Liu J, Heldens S, Zhang J, Lee WP, Roose-Girma M, Dixit VM. Non-canonical inflammasome activation targets caspase-11. Nature 2011, 479:117-121. 10.1038/nature10558, 22002608.
40. Schulze J, Bickert T, Beil FT, Zaiss MM, Albers J, Wintges K, Streichert T, Klaetschke K, Keller J, Hissnauer TN, Spiro AS, Gessner A, Schett G, Amling M, McKenzie AN, Horst AK, Schinke T. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J Bone Miner Res 2011, 26:704-717. 10.1002/jbmr.269, 20939024.
41. Zaiss MM, Kurowska-Stolarska M, Bohm C, Gary R, Scholtysek C, Stolarski B, Reilly J, Kerr S, Millar NL, Kamradt T, McInnes IB, Fallon PG, David JP, Liew FY, Schett G. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss. J Immunol 2011, 186:6097-6105. 10.4049/jimmunol.1003487, 21515798.
42. Hoshino K, Kashiwamura S, Kuribayashi K, Kodama T, Tsujimura T, Nakanishi K, Matsuyama T, Takeda K, Akira S. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J Exp Med 1999, 190:1541-1548. 10.1084/jem.190.10.1541, 2195706, 10562328.
43. Coyle AJ, Lloyd C, Tian J, Nguyen T, Erikkson C, Wang L, Ottoson P, Persson P, Delaney T, Lehar S, Lin S, Poisson L, Meisel C, Kamradt T, Bjerke T, Levinson D, Gutierrez-Ramos JC. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med 1999, 190:895-902. 10.1084/jem.190.7.895, 2195643, 10510079.
44. Mangan NE, Dasvarma A, McKenzie AN, Fallon PG. T1/ST2 expression on Th2 cells negatively regulates allergic pulmonary inflammation. Eur J Immunol 2007, 37:1302-1312. 10.1002/eji.200636520, 17407196.
45. Oboki K, Ohno T, Kajiwara N, Arae K, Morita H, Ishii A, Nambu A, Abe T, Kiyonari H, Matsumoto K, Sudo K, Okumura K, Saito H, Nakae S. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci USA 2010, 107:18581-18586. 10.1073/pnas.1003059107, 2972966, 20937871.
46. Louten J, Rankin AL, Li Y, Murphy EE, Beaumont M, Moon C, Bourne P, McClanahan TK, Pflanz S, de Waal Malefyt R. Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Int Immunol 2011, 23:307-315. 10.1093/intimm/dxr006, 21422152.
47. Keller J, Catala-Lehnen P, Wintges K, Schulze J, Bickert T, Ito W, Horst AK, Amling M, Schinke T. Transgenic over-expression of interleukin-33 in osteoblasts results in decreased osteoclastogenesis. Biochem Biophys Res Commun 2012, 417:217-222. 10.1016/j.bbrc.2011.11.088, 22142849.
48. Luzina IG, Pickering EM, Kopach P, Kang PH, Lockatell V, Todd NW, Papadimitriou JC, McKenzie AN, Atamas SP. Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion. J Immunol 2012, 189:403-410. 10.4049/jimmunol.1200259, 22634619.
49. Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem 2009, 284:19420-19426. 10.1074/jbc.M901744200, 2740567, 19465481.
50. Garlanda C, Anders HJ, Mantovani A. TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol 2009, 30:439-446. 10.1016/j.it.2009.06.001, 19699681.
51. miRBase. , http://www.mirbase.org
52. Corr M, Crain B. The role of FcgammaR signaling in the K/B x N serum transfer model of arthritis. J Immunol 2002, 169:6604-6609.